Together, these findings demonstrate that CD8+ TN cells are heterogeneous in differentiating into IL-17A-producing effector cells and these different abilities are associated with the distinctly different robustness of IBD outcomes observed in CD5lo, Ly6C−, and Ly6C+ subsets. Here, IL17A is linked to inflammatory bowel disease.